Cerus (CERS) Upgraded to Sell by ValuEngine

Cerus (NASDAQ:CERS) was upgraded by ValuEngine from a “strong sell” rating to a “sell” rating in a note issued to investors on Thursday.

A number of other equities analysts have also recently issued reports on CERS. Cowen set a $6.00 price objective on shares of Cerus and gave the company a “buy” rating in a research note on Thursday, October 5th. Robert W. Baird reaffirmed a “buy” rating and issued a $5.00 price objective on shares of Cerus in a research note on Friday, December 1st. Zacks Investment Research raised shares of Cerus from a “hold” rating to a “buy” rating and set a $4.00 price objective on the stock in a research note on Wednesday, November 8th. BTIG Research reaffirmed a “neutral” rating on shares of Cerus in a research note on Friday, December 8th. Finally, BidaskClub cut shares of Cerus from a “hold” rating to a “sell” rating in a research note on Tuesday, December 12th. Two equities research analysts have rated the stock with a sell rating, two have given a hold rating and four have issued a buy rating to the company. Cerus presently has an average rating of “Hold” and an average target price of $6.17.

Shares of Cerus (NASDAQ CERS) traded up $0.13 during trading on Thursday, hitting $3.72. 493,639 shares of the company were exchanged, compared to its average volume of 583,966. The company has a current ratio of 3.71, a quick ratio of 3.11 and a debt-to-equity ratio of 0.80. The firm has a market capitalization of $424.40, a price-to-earnings ratio of -6.31 and a beta of 1.93. Cerus has a fifty-two week low of $1.93 and a fifty-two week high of $4.70.

Cerus (NASDAQ:CERS) last issued its quarterly earnings results on Thursday, November 2nd. The biotechnology company reported ($0.12) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.03. The business had revenue of $10.80 million during the quarter, compared to analyst estimates of $11.95 million. Cerus had a negative net margin of 159.35% and a negative return on equity of 142.18%. Cerus’s revenue for the quarter was up 5.9% compared to the same quarter last year. During the same quarter last year, the business posted ($0.14) earnings per share. equities analysts anticipate that Cerus will post -0.57 earnings per share for the current fiscal year.

A number of hedge funds have recently made changes to their positions in CERS. Elk Creek Partners LLC boosted its stake in Cerus by 32.3% in the second quarter. Elk Creek Partners LLC now owns 5,739,285 shares of the biotechnology company’s stock valued at $14,406,000 after acquiring an additional 1,402,106 shares during the last quarter. Ark Investment Management LLC boosted its position in shares of Cerus by 126.5% during the second quarter. Ark Investment Management LLC now owns 1,680,925 shares of the biotechnology company’s stock worth $4,219,000 after purchasing an additional 938,647 shares in the last quarter. First Midwest Bank Trust Division boosted its position in shares of Cerus by 50.3% during the third quarter. First Midwest Bank Trust Division now owns 1,078,277 shares of the biotechnology company’s stock worth $2,944,000 after purchasing an additional 360,785 shares in the last quarter. Vanguard Group Inc. boosted its position in shares of Cerus by 3.9% during the second quarter. Vanguard Group Inc. now owns 4,892,503 shares of the biotechnology company’s stock worth $12,281,000 after purchasing an additional 184,076 shares in the last quarter. Finally, Premier Asset Management LLC bought a new position in shares of Cerus during the third quarter worth $348,000. 56.44% of the stock is currently owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION NOTICE: “Cerus (CERS) Upgraded to Sell by ValuEngine” was originally posted by Ticker Report and is the sole property of of Ticker Report. If you are reading this piece on another publication, it was stolen and republished in violation of US & international copyright and trademark law. The original version of this piece can be viewed at https://www.tickerreport.com/banking-finance/3126077/cerus-cers-upgraded-to-sell-by-valuengine.html.

Cerus Company Profile

Cerus Corporation is a biomedical products company. The Company is engaged in developing and commercializing the INTERCEPT Blood System for blood safety. The Company operates through blood safety segment. The Company’s INTERCEPT Blood System is based on its technology for controlling biological replication, and is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.

Analyst Recommendations for Cerus (NASDAQ:CERS)

Receive News & Ratings for Cerus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerus and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


Leave a Reply

© 2006-2018 Ticker Report. Google+.